COMMUNIQUÉS West-GlobeNewswire

Viemed Healthcare Announces Third Quarter 2024 Financial Results

06/11/2024 - 22:45

LAFAYETTE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced [...]

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

06/11/2024 - 22:45

Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp . (Nasdaq: OCX), a diagnostics technology company, announced [...]

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

06/11/2024 - 22:49

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced [...]

Grant of Warrants

04/11/2024 - 18:44

4 November 2024 Announcement no. 21 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, November 4, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has [...]

Sienna Announces Change of timing to Third Quarter 2024 Conference Call

04/11/2024 - 19:00

MARKHAM, Ontario, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a change in the timing of its upcoming 2024 third quarter conference call with the [...]

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

04/11/2024 - 20:36

WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T [...]

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

04/11/2024 - 20:41

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) announces that further to its news release of October 18, [...]

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

04/11/2024 - 21:11

Inovalon Unveils New Research, Products, and Solutions to Tackle Healthcare’s Most Complex Challenges BOWIE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inovalon , a leading provider of cloud-based software solutions [...]

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/11/2024 - 22:00

WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/11/2024 - 22:00

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2024 it granted stock options to purchase an aggregate of 17,712 shares of [...]

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

04/11/2024 - 22:01

-- Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8) at three months on setmelanotide therapy; mean BMI decrease of 21.3% in patients (n=5) who reached six [...]

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

04/11/2024 - 22:01

SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]

Inspire Medical Systems, Inc. Announces Third Quarter 2024 Financial Results and Updates 2024 Outlook

04/11/2024 - 22:02

Inspire Reports Year-over-Year Revenue Growth of 33% and Earnings per Share of $0.60 in the Third Quarter MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the [...]

Supernus Announces Third Quarter 2024 Financial Results

04/11/2024 - 22:05

Net sales of Qelbree ® increased 68% in the third quarter of 2024, compared to the same period in 2023. Net sales of Qelbree of $62.4 million and $166.9 million in the third quarter and first nine months of 2024, [...]

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

04/11/2024 - 22:05

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will [...]

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

04/11/2024 - 22:05

– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing [...]

Amwell Makes Grants to New Employees Under Inducement Plan

04/11/2024 - 22:05

BOSTON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in digital care, today announced that, on November 4, 2024, it made a grant of restricted stock units (“RSUs”) covering 254,227 shares of its [...]

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

04/11/2024 - 22:05

RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

04/11/2024 - 22:05

First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC Topline Phase 1 dose escalation data for FHD- [...]